ArticleLupus science & medicine2015
Characterising the immune profile of the kidney biopsy at lupus nephritis flare differentiates early treatment responders from non-responders.
Article in Lupus science & medicine, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 47 citations in OpenAlex.
- Urine proteins reveal distinct coagulation and complement cascades underlying acute versus chronic lupus nephritis.The Journal of clinical investigation · 2025Article
- Renal remodeling by CXCL10-CXCR3 axis-recruited mesenchymal stem cells and subsequent IL4I1 secretion in lupus nephritis.Signal transduction and targeted therapy · 2024Article
- Molecular profiling of kidney compartments from serial biopsies differentiate treatment responders from non-responders in lupus nephritis.Kidney international · 2022Article
- Prediction models of treatment response in lupus nephritis.Kidney international · 2022Article
- Advances in Lupus Nephritis Pathogenesis: From Bench to Bedside.International journal of molecular sciences · 2021Review
- A Novel Inflammatory Dendritic Cell That Is Abundant and Contiguous to T Cells in the Kidneys of Patients With Lupus Nephritis.Frontiers in immunology · 2021Article
- Renal deposits of complement factors as predictors of end-stage renal disease and death in patients with lupus nephritis.Rheumatology (Oxford, England) · 2020Article
- Review: transcriptome and trans-omics analysis of systemic lupus erythematosus.Inflammation and regeneration · 2020Review
- Rethinking Lupus Nephritis Classification on a Molecular Level.Journal of clinical medicine · 2019Article
- Immune gene expression in kidney biopsies of lupus nephritis patients at diagnosis and at renal flare.Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association · 2019Article
- Review
- Transcriptomic and Epigenetic Alterations in Dendritic Cells Correspond With Chronic Kidney Disease in Lupus Nephritis.Frontiers in immunology · 2019Article
- Induction Therapy for Lupus Nephritis: the Highlights.Current rheumatology reports · 2018Review
- The contribution of the programmed cell death machinery in innate immune cells to lupus nephritis.Clinical immunology (Orlando, Fla.) · 2017Review
- Enhanced Inflammasome Activity in Systemic Lupus Erythematosus Is Mediated via Type I Interferon-Induced Up-Regulation of Interferon Regulatory Factor 1.Arthritis & rheumatology (Hoboken, N.J.) · 2017Article
- Molecular imaging of the kidney in lupus nephritis to characterize response to treatment.Translational research : the journal of laboratory and clinical medicine · 2017Article
- Biomarkers of lupus nephritis histology and flare: deciphering the relevant amidst the noise.Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association · 2017Review
- Current and Emerging Therapies for Lupus Nephritis.Journal of the American Society of Nephrology : JASN · 2016Review
- Hurdles to the introduction of new therapies for immune-mediated kidney diseases.Nature reviews. Nephrology · 2016Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 2 institutions in 2 countries.
Funding
Abstract
introductionThe kidney biopsy is used to diagnose and guide initial therapy in patients with lupus nephritis (LN). Kidney histology does not correlate well with clinical measurements of kidney injury or predict how patients will respond to standard-of-care immunosuppression. We postulated that the gene expression profile of kidney tissue at the time of biopsy may differentiate patients who will from those who will not respond to treatment.
methodsThe expression of 511 immune-response genes was measured in kidney biopsies from 19 patients with proliferative LN and 4 normal controls. RNA was extracted from formalin-fixed, paraffin-embedded kidney biopsies done at flare. After induction therapy, 5 patients achieved a complete clinical response (CR), 10 had a partial response (PR) and 4 patients were non-responders (NRs). Transcript expression was compared with normal controls and between renal response groups.
resultsA principal component analysis showed that intrarenal transcript expression from normal kidney, CR biopsies and NR biopsies segregated from each other. The top genes responsible for CR clustering included several interferon pathway genes (STAT1, IRF1, IRF7, MX1, STAT2, JAK2), while complement genes (C1R, C1QB, C6, C9, C5, MASP2) were mainly responsible for NR clustering. Overall, 35 genes were uniquely expressed in NR compared with CR. Pathway analysis revealed that interferon signalling and complement activation pathways were upregulated in both groups, while BAFF, APRIL, nuclear factor-κB and interleukin-6 signalling were increased in CR but suppressed in NR.
conclusionsThese data suggest that molecular profiling of the kidney biopsy at LN flare may be useful in predicting treatment response to induction therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.